Key result
Mean PASS was significantly higher in pheochromocytomas >6 cm compared to those ≤6 cm (4.4 vs. 3.3, p=0.04), but neither tumor size nor PASS could reliably predict malignancy.
Why the study?
Can tumor size and the Pheochromocytoma of the adrenal gland scaled score (PASS) predict malignancy in patients with pheochromocytomas?
Observational (n=93)
Can tumor size and the Pheochromocytoma of the adrenal gland scaled score (PASS) predict malignancy in patients with pheochromocytomas?
Absolute Event Rate: 4.4% vs 3.3%
p-value: p=0.04
Neither tumor size > 6 cm nor the PASS score can reliably predict malignancy in pheochromocytomas.
No takes yet. Share an insight, caveat, or question.
Neither tumor size nor PASS reliably predicts pheochromocytoma malignancy; leaves open need for validated predictors in prospective studies.
Agarwal et al. (2010) conducted an observational in Pheochromocytoma (n=93). Tumor size > 6 cm vs. Tumor size ≤ 6 cm was evaluated on Mean PASS score (p=0.04). Mean PASS was significantly higher in pheochromocytomas >6 cm compared to those ≤6 cm (4.4 vs. 3.3, p=0.04), but neither tumor size nor PASS could reliably predict malignancy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: